Although Pontin and Reptin have other binding partners that are relevant for cancer progression such as β-catenin and Myc31, 37, our results, combined with the frequent aberrant E2f activity in cancer, suggest that their recruitment by E2f1 may be a common mechanism to drive cancer progression. Here, RUVBL2 is linked to cancer.